Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity

Human respiratory syncytial virus (RSV) is a cause of lower respiratory tract infection in infants, young children, and older adults. There is no licensed vaccine and prophylactic treatment options are limited. The RSV fusion (F) glycoprotein is a target of host immunity and thus a focus for vaccine...

Full description

Bibliographic Details
Main Authors: Nita Patel, Jing-Hui Tian, Rhonda Flores, Kelsey Jacobson, Michelle Walker, Alyse Portnoff, Mimi Gueber-Xabier, Michael J. Massare, Greg Glenn, Larry Ellingsworth, Gale Smith
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/8/4/607